首頁 > 市場調查報告書 > 醫療設備

生技設備癌症

癌症腫瘤分析市場規模、佔有率和成長分析（按癌症類型、生物標記類型、技術、方法、應用和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897558

癌症腫瘤分析市場規模、佔有率和成長分析（按癌症類型、生物標記類型、技術、方法、應用和地區分類）－2026-2033年產業預測

Cancer Tumor Profiling Market Size, Share, and Growth Analysis, By Cancer type (Breast Cancer, Lung Cancer), By Biomarker type (Genomic Biomarker, Protein Biomarker), By Technology, By Technique, By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球癌症腫瘤分析市場規模預計在 2024 年達到 134.4 億美元，從 2025 年的 149.3 億美元成長到 2033 年的 346.6 億美元，在預測期（2026-2033 年）內複合年成長率為 11.1%。

全球癌症腫瘤分析市場正經歷強勁成長，這主要得益於癌症發病率的上升以及對生物標記在檢測和治療中日益成長的依賴。此外，研究經費的增加、技術的創新以及向個人化醫療和照護現場診斷的轉變也進一步推動了這一成長，為行業相關人員創造了巨大的機會。儘管新冠疫情暫時影響了癌症檢測和診斷，但長期前景仍然樂觀。市場中的關鍵細分領域——基因組學、蛋白質組學、表觀遺傳學和代謝體學——預計將持續成長，其中基因組學預計將呈現最高的成長率。該技術在識別促進癌細胞增殖的基因突變方面發揮關鍵作用，從而促進先進的腫瘤分析，有助於指導治療策略並改善患者預後。

全球癌症腫瘤分析市場促進因素

全球癌症腫瘤分析市場的成長主要受全球癌症發生率上升的驅動。癌症病例激增與多種因素相關，例如人口老化和成長，以及各種癌症風險因子盛行率的變化。癌症本身的複雜性，受多種因素影響，進一步加劇了這一局面。隨著越來越多的人被診斷出患有各種類型的癌症，對綜合腫瘤分析服務的需求正在加速成長，這凸顯了開發先進診斷工具以應對癌症檢測和治療複雜性的必要性。

阻礙因素

樣本採集和保存方面的技術難題對全球癌症腫瘤譜分析市場的擴張構成重大障礙。醫療保健領域個人化醫療的快速發展已經徹底改變了多種疾病的識別、分類和治療方式，使其成為主流臨床實踐的重要組成部分。儘管腫瘤學領域取得了顯著進展，但這些進展固有的風險和併發症可能會阻礙市場整體成長。解決這些技術難題對於充分發揮腫瘤譜分析的潛力、改善癌症治療的患者照護和療效至關重要。

全球癌症腫瘤分析市場趨勢

全球癌症腫瘤分析市場正經歷顯著成長，這主要得益於體學數據的整合和液態生物檢體技術的進步。個人化醫療的興起也推動了這一趨勢，它正在革新癌症的識別、分類和治療方式。隨著個人化醫療方法在臨床實踐中逐漸成為主流，在各種腫瘤學應用中也得到了越來越廣泛的應用。這種轉變不僅提高了診斷的準確性，也改善了治療效果，從而促進了更有效、更具針對性的癌症治療生態系統的建構。因此，預計在革新全球腫瘤學實踐的技術創新驅動下，該市場將迎來強勁成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Illumina, Inc.（USA）
QIAGEN NV（Netherlands）
NeoGenomics, Inc.（USA）
Thermo Fisher Scientific（USA）
Roche Diagnostics（Switzerland）
Guardant Health, Inc.（USA）
Foundation Medicine, Inc.（USA）
Sysmex Corporation（Japan）
Becton, Dickinson and Company（BD）（USA）
F. Hoffmann-La Roche Ltd.（Switzerland）
Merck & Co., Inc.（USA）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
AstraZeneca（UK）
Bristol-Myers Squibb Company（USA）
Johnson & Johnson（USA）
Danaher Corporation（USA）
Abbott Laboratories（USA）

結論與建議

簡介目錄

Product Code: SQMIG35G2114

Global Cancer Tumor Profiling Market size was valued at USD 13.44 Billion in 2024 and is poised to grow from USD 14.93 Billion in 2025 to USD 34.66 Billion by 2033, growing at a CAGR of 11.1% during the forecast period (2026-2033).

The global market for cancer tumor profiling is experiencing robust growth, driven by the rising incidence of cancer and the increasing reliance on biomarkers for detection and treatment. This expansion is further fueled by heightened research funding, technological innovations, and the shift towards personalized medicine and point-of-care diagnostics, creating significant opportunities for industry players. Although the COVID-19 pandemic temporarily impacted cancer testing and diagnosis, the long-term outlook remains optimistic. Key segments within the market-genomics, proteomics, epigenetics, and metabolomics-are anticipated to flourish, with genomics expected to showcase the highest growth rate. This technique plays a critical role in identifying gene mutations that allow cancer cells to thrive, facilitating advanced tumor profiling to inform treatment strategies and improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Tumor Profiling Market Segments Analysis

Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Tumor Profiling Market

The global cancer tumor profiling market is significantly driven by the rising incidence of cancer worldwide. This surge in cancer cases can be linked to multiple factors, including an aging population and demographic growth, alongside shifts in the prevalence of various cancer risk factors. The intricate nature of cancer, influenced by a diverse array of causes, further exacerbates the situation. As more individuals are diagnosed with different forms of the disease, the demand for comprehensive tumor profiling services is accelerating, highlighting the essential need for advanced diagnostic tools that cater to the complexities of cancer detection and management.

Restraints in the Global Cancer Tumor Profiling Market

Challenges associated with technical issues in the collection and storage of samples pose significant obstacles to the expansion of the global cancer tumor profiling market. As personalized medicine rapidly evolves within healthcare, it transforms the identification, classification, and treatment of various diseases, making it an integral part of mainstream clinical practice. While advancements in oncology are notable, the inherent risks and complications related to these advancements can impede overall market growth. Addressing these technical constraints is critical for harnessing the full potential of tumor profiling to enhance patient care and outcomes in cancer treatment.

Market Trends of the Global Cancer Tumor Profiling Market

The Global Cancer Tumor Profiling market is experiencing significant growth driven by the integration of omics data and advancements in liquid biopsy technologies. This trend is underpinned by the rise of personalized medicine, which is revolutionizing how cancers are identified, classified, and treated. As personalized approaches become mainstream in clinical practice, they are increasingly being utilized across a range of oncological applications. This shift not only enhances diagnostic accuracy but also improves treatment outcomes, leading to a more effective and targeted cancer care ecosystem. Consequently, the market is poised for robust expansion as innovations reshape oncology practices worldwide.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2026-2033)

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Other Cancer

Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2026-2033)

Market Overview
Genomic Biomarker
Protein Biomarker

Global Cancer Tumor Profiling Market Size by Technology & CAGR (2026-2033)

Market Overview
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others

Global Cancer Tumor Profiling Market Size by Technique & CAGR (2026-2033)

Market Overview
Genomics
Proteomics
Metabolomics
Epigenetics

Global Cancer Tumor Profiling Market Size by Application & CAGR (2026-2033)

Market Overview
Research
Biomarker Discovery
Personalized Medicine
Clinical Application
Diagnostics
Prognostics
Screening
Treatment and Monitoring

Global Cancer Tumor Profiling Market Size & CAGR (2026-2033)

North America (Cancer type, Biomarker type, Technology, Technique, Application)
- US
- Canada
Europe (Cancer type, Biomarker type, Technology, Technique, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments